Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc is positioned favorably in the clinical-stage biopharmaceutical sector, focusing on innovative bifunctional therapies for solid tumors, particularly through its lead program, ficerafusp alfa, which exhibits promising durability data with a 9.8-month median progression-free survival in HPV-negative patients. The company's strategic reduction in target enrollment for the FORTIFI-HN01 trial to approximately 650 patients aims to streamline costs and accelerate time to market, which could alleviate investor concerns regarding competitive pressures. Additionally, ficerafusp alfa has demonstrated superior complete response rates compared to its main competitor, suggesting a strong potential for meaningful therapeutic outcomes and bolstering the overall attractiveness of Bicara's stock.

Bears say

Bicara Therapeutics Inc faces significant risks related to the efficacy and safety of its lead program, ficerafusp alfa, which may impede its development and commercial prospects. The company could also encounter delays in advancing ficerafusp alfa into critical registrational trials and may struggle to achieve favorable clinical results or obtain timely regulatory approvals, compounding concerns about its competitive position in a rapidly evolving landscape. Additionally, the risk of long-term dilution and failure to meet sales estimates further exacerbates the company's financial uncertainties, impacting investor confidence in its ability to deliver sustainable growth.

BCAX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 6 analysts, BCAX has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.